SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Thomas A Zelniker
Stephen D Wiviott
Itamar Raz
Kyungah Im
Erica L Goodrich
Marc P Bonaca
Ofri Mosenzon
Eri T Kato
Avivit Cahn
Remo H M Furtado
Deepak Bhatt
Lawrence A Leiter
John P H Wilding
Marc S Sabatine

SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure.

Read More

Lancet (London, England), ISSN: 1474-547X, Vol: 393, Issue: 10166, Page: 31-39